The global Single-Molecule Real-Time (SMRT) sequencing market is witnessing robust growth as researchers and healthcare organizations increasingly adopt long-read sequencing technologies to unlock deeper genomic insights. The market is projected to grow from USD 2.92 billion in 2025 to USD 5.32 billion by 2030, registering a CAGR of 12.8% during the forecast period.
The growing demand for highly accurate long-read sequencing, improved detection of structural variants, and comprehensive analysis of complex genomic regions is accelerating market expansion. As genomics continues to transform precision medicine, cancer research, rare disease diagnosis, and population-scale studies, SMRT sequencing has emerged as a critical technology for generating high-quality genomic data.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=161993235
Why SMRT Sequencing is Gaining Momentum
Traditional short-read sequencing technologies have revolutionized genomics over the last decade, but they often face limitations when analyzing repetitive DNA sequences, structural variants, and highly complex genomic regions. SMRT sequencing addresses these challenges by producing significantly longer reads with exceptional accuracy.
Key advantages include:
- Enhanced structural variant detection
- Improved genome assembly and phasing
- Comprehensive characterization of repetitive regions
- Accurate epigenetic analysis
- Better identification of rare genetic variations
- Increased utility in clinical and translational research
As genomic medicine becomes more personalized, researchers are increasingly relying on SMRT sequencing to generate complete and actionable genetic information.
Strategic Collaborations Accelerating Innovation
The competitive landscape continues to evolve through partnerships, product innovations, and geographic expansion initiatives.
A notable example occurred in June 2025, when PacBio and Ultima Genomics announced a strategic collaboration aimed at developing high-throughput sequencing solutions that combine SMRT long-read data with cost-efficient short-read sequencing technologies. This partnership seeks to support large-scale population genomics projects and clinical research programs by delivering greater sequencing accuracy while controlling costs.
Such collaborations highlight the industry’s focus on creating integrated sequencing ecosystems capable of supporting next-generation genomic applications.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=161993235
Key Companies Shaping the SMRT Sequencing Market
Several industry leaders are playing critical roles in advancing SMRT sequencing technologies and enabling broader adoption across research and clinical environments.
Illumina, Inc.
Although primarily recognized for its short-read sequencing platforms, Illumina remains a major contributor to the SMRT sequencing ecosystem. The company’s NovaSeq and NextSeq platforms are frequently combined with long-read sequencing data to create hybrid sequencing workflows.
Illumina supports:
- Population genomics studies
- Cancer research programs
- Human genome sequencing initiatives
- Single-cell genomics
- Spatial biology applications
- Cloud-based bioinformatics analysis
By enabling researchers to integrate short-read depth with long-read accuracy, Illumina helps laboratories achieve comprehensive genomic characterization while maintaining cost efficiency.
Thermo Fisher Scientific
Thermo Fisher Scientific serves as a critical technology enabler within the SMRT sequencing ecosystem. Through its broad portfolio of laboratory instruments, automation systems, quality-control tools, and informatics solutions, the company helps laboratories standardize and optimize sequencing workflows.
Key contributions include:
- Library preparation technologies
- Sample-preparation automation
- Quality control instrumentation
- Genomic informatics platforms
- Multi-omics research support
- Clinical and translational laboratory solutions
The company’s strong presence in clinical diagnostics and translational medicine positions it well to support integrated DNA, RNA, and protein analysis workflows that increasingly incorporate SMRT sequencing data.
Agilent Technologies
Agilent Technologies plays a vital role in ensuring sample quality and workflow reliability for SMRT sequencing applications.
Its solutions include:
- Bioanalyzer systems
- Fragment Analyzer platforms
- Electrophoresis technologies
- Target enrichment solutions
- Laboratory automation systems
- Analytical instrumentation
These technologies help researchers optimize library preparation, assess sample quality, and improve sequencing performance, ultimately contributing to higher-quality long-read genomic data.
Emerging Applications Expanding Market Opportunities
The adoption of SMRT sequencing is expanding beyond traditional research settings into numerous high-growth applications.
Rare Disease Diagnostics
Long-read sequencing enables the identification of genetic mutations and structural variants that may be missed by conventional sequencing methods, improving diagnostic accuracy for rare and inherited disorders.
Oncology Research
Cancer researchers increasingly utilize SMRT sequencing to study complex tumor genomes, identify actionable mutations, and better understand cancer evolution and resistance mechanisms.
Population Genomics
Large-scale sequencing initiatives require technologies capable of generating comprehensive genomic data across diverse populations. SMRT sequencing provides critical information for genomic diversity studies and precision medicine initiatives.
Agricultural Genomics
Plant and animal breeding programs are leveraging long-read sequencing to improve genome assemblies, identify beneficial traits, and accelerate genetic improvement strategies.
Microbial and Infectious Disease Research
SMRT sequencing offers complete microbial genome characterization, supporting pathogen surveillance, antimicrobial resistance monitoring, and outbreak investigations.
Market Ranking and Competitive Landscape
The SMRT sequencing market exhibits a relatively consolidated structure, with leading companies leveraging technological innovation, strategic collaborations, and comprehensive product portfolios to strengthen their market positions.
Market leaders are increasingly focusing on:
- Technology integration
- Workflow automation
- Cloud-based bioinformatics
- Multi-omics capabilities
- Strategic partnerships
- Global expansion initiatives
The growing convergence of long-read and short-read sequencing technologies is creating opportunities for hybrid sequencing workflows that deliver greater accuracy, scalability, and cost efficiency.
Future Outlook
The future of the SMRT sequencing market appears highly promising as demand for comprehensive genomic analysis continues to grow across healthcare, biotechnology, pharmaceutical, and academic sectors.
Key growth drivers expected to shape the market through 2030 include:
- Rising adoption of precision medicine
- Increasing investments in genomics research
- Expanding population-scale sequencing projects
- Growing demand for structural variant analysis
- Advancements in sequencing chemistry and bioinformatics
- Integration of multi-omics research approaches
As genomic research moves toward more complete and clinically actionable insights, SMRT sequencing technologies are expected to play an increasingly important role in enabling the next generation of discoveries and precision healthcare solutions.
Conclusion
The Single-Molecule Real-Time (SMRT) sequencing market is entering a period of significant growth, driven by the need for highly accurate long-read sequencing and deeper genomic understanding. With the market projected to reach USD 5.32 billion by 2030, leading companies such as PacBio, Illumina, Thermo Fisher Scientific, and Agilent Technologies are advancing technologies and forming strategic partnerships that expand the capabilities of modern genomics. As precision medicine, population genomics, and multi-omics research continue to evolve, SMRT sequencing will remain a cornerstone technology shaping the future of life sciences and healthcare innovation.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=161993235